Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 459-467

  Grzeskowiak, Luke E ^a   Gilbert, Andrew L ^a   Morrison, Janna L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Drug exposure; Methodology; Pharmacoepidemiology; Pharmacy records; Pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

BIRTH WEIGHT; CARDIOVASCULAR MALFORMATION; CONGENITAL MALFORMATION; DOSE RESPONSE; DRUG USE; GESTATIONAL AGE; HEART SEPTUM DEFECT; HUMAN; LOW BIRTH WEIGHT; PREGNANCY; PREGNANCY OUTCOME; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

ABNORMALITIES, DRUG-INDUCED; BIRTH WEIGHT; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MATERNAL-FETAL EXCHANGE; MEDICAL RECORD LINKAGE; MEDICATION ADHERENCE; PHARMACOEPIDEMIOLOGY; PREGNANCY; PREMATURE BIRTH; PRESCRIPTION DRUGS; SEROTONIN UPTAKE INHIBITORS;

EID: 84864279773     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1154-9     Document Type: Review

References (30)

1. Mitchell A (2003) Systematic identification of drugs that cause birth defects - a new opportunity [editorial]. N Engl J Med 349 (26):2556-2559 (Pubitemid 38010084)
2. Irl C, Hasford J (2000) Assessing the safety of drugs in pregnancy: the role of prospective cohort studies. Drug Saf 22 (3):169-177 (Pubitemid 30157577)
3. Källén BAJ (2005) Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto) 45 (2):44-51 (Pubitemid 41657755)
4. Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C (2008) Using observational cohort data for studying drug effects on pregnancy outcome - methodological considerations. Reprod Toxicol 26(1):36-41
5. Andrews EB, Tennis P (2007) Promise and pitfalls of administrative data in evaluating pregnancy outcomes. Pharmacoepidemiol Drug Saf 16(11):1181-1183 (Pubitemid 350120641)
6. Holman CDJ, Bass JA, Rouse IL, Hobbs MST (1999) Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23(5):453-459 (Pubitemid 29479210)
7. Brent RL (2001) Addressing environmentally caused human birth defects. Pediatr Rev 22(5):153-165 (Pubitemid 34074084)
8. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM (2011) Patterns of antidepressant medication use among pregnant women in a united states population. J Clin Pharmacol 51(2):264-270
9. Grzeskowiak LE, Gilbert AL, Morrison JL (2011) Investigating outcomes following the use of SSRIs for treating depression in pregnancy: a focus on methodological issues. Drug Saf 34 (11):1027-1048
10. Malm H, Klaukka T, Neuvonen PJ (2005) Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106(6):1289-1296 (Pubitemid 41668948)
11. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C (2008) Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 83(1):68-76 (Pubitemid 351317794)
12. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH (2009) Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339(231):b3569
13. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M (2010) Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2:29-36
14. Colvin L, Slack Smith L, Stanley FJ, Bower C (2011) Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 91:142-152
15. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D et al (2007) Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 16(10):1086-1094 (Pubitemid 350020061)
16. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D (2007) First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80(1):18-27
17. Wogelius P, Nørgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB et al (2006) Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17(6):701-704 (Pubitemid 44655607)
18. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C et al (2006) Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Ostet Gynecol 194(4):961-966
19. Cole JA, Ephross SA, Cosmatos IS, Walker AM (2007) Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16(10):1075-1085 (Pubitemid 350020060)
20. Simon GE, Cunningham ML, Davis RL (2002) Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159(12):2055-2061 (Pubitemid 35423865)
21. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2006) Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63(8):898-906 (Pubitemid 44188483)
22. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2008) Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 192(5):338-343 (Pubitemid 351692377)
23. Bakker MK, Kolling P, van den Berg PB, de Walle HEK, de Jong van den Berg LTW (2008) Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 65(4):600-606 (Pubitemid 351365128)
24. Kallen B, Nilsson E, Olausson PO (2011) Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol 67(8):839-845
25. Tanner K, Sabrine N, Wren C (2005) Cardiovascular malformations among preterm infants. Pediatrics 116(6):e833-e838 (Pubitemid 46061098)
26. Toh S, Mitchell AA, Werler MM, Hernández-Díaz S (2008) Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 167(6):633-640 (Pubitemid 351430939)
27. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM (2007) Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16 (5):474-484 (Pubitemid 46824268)
28. Espnes MG, Bjørge T, Engeland A (2011) Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 20:243-248
29. Stephansson O, Granath F, Svensson T (2011) Drug use during pregnancy in Sweden-assessed by the Prescribed Drug Register and the Medical Birth Register. Clin Epidemiol 3:43-50
30. Olesen C, Sondergaard C, Thrane N, Lauge Nielsen G, de Jong-van den Berg L, Olsen J et al (2001) Do pregnant women report use of dispensed medications? Epidemiology 12(5):497-501 (Pubitemid 32761987)